We can't find the internet
Attempting to reconnect
Something went wrong!
Hang in there while we get back on track
Psychedelics Startups for the Future of Mental Health. Panel moderated by Cate Lawrence at Tech.eu
Discover the future of mental health at the intersection of psychedelics and tech, where digital phenotyping, therapy platforms, and biosynthesis are driving innovation and-breaking down stigma, moderated by Cate Lawrence at Tech.eu.
- Digital phenotyping through mobile phone usage can aid in tracking people’s mental health.
- Psychedelic treatments are promising, but not everyone responds to them and it can be demoralizing.
- The stigma surrounding psychedelics is still present, but accelerating clinical trials and research will help reduce it.
- Therapist training is crucial for administering psychedelic treatments, and digital therapy platforms are emerging.
- The pharma industry is slow to adopt psychedelic treatments, but changes are expected in the next 10 years.
- Veteran patients have benefited from psychedelic treatments, particularly for PTSD and depression.
- Biosynthesis and biotech companies are working on novel psychedelic compounds, such as LSD and psilocybin.
- The-global movement is shifting away from prohibition and towards mainstream acceptance of psychedelics.
- Synthetic forms of naturally-occurring psychedelics may not be the most effective or sustainable approach.
- Telemedicine is expanding access to psychedelic treatments, andтю will likely become a standard treatment option.
- Patient stories and advocacy are crucial for shifting public perception and driving change.
- The intersection of psychedelics and mental health is complex, with many unaddressed issues, such as addiction and eating disorders.
- Innovation in the psychedelic space is happening, but it requires investment, infrastructure, and regulatory support.
- There is a growing demand for psychedelic education and training programs for healthcare professionals.